Company intelligence / Profile preview

Ocugenix

Pittsburgh, Pennsylvania, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Phase 1

Overview

Ocugenix develops small molecule therapies for angio-fibrotic diseases of the eye such as wet macular degeneration and diabetic retinopathy. Their lead compound, Ocu‑110, aims to regress pathological blood vessels and fibrosis. The company’s approach offers hope for restoring lost sight by resolving aberrant wound responses in retinal disease. No published clinical results are available yet.

Therapeutic areas: Ophthalmology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

OCU-10-C-110

Partnerships

Innovation Works (investor/partner)

Beyond the preview

Go deeper on Ocugenix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ocugenix.

Explore the full profile